

# **Gastrointestinal Lymphoma**

**Protocol applies to Hodgkin and non-Hodgkin lymphomas of the gastrointestinal tract.**

---

*Protocol revision date: January 2005  
No AJCC/UICC TNM staging system*

## **Procedures**

- **Cytology** (No Accompanying Checklist)
- **Incisional Biopsy** (No Accompanying Checklist)
- **Resection**

## **Author**

Carolyn Compton, MD, PhD

Department of Pathology, McGill University, Montreal, Quebec, Canada  
For the Members of the Cancer Committee, College of American Pathologists

**Previous contributor:** Leslie H. Sobin, MD

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

## Summary of Changes to Checklist(s)

*Protocol revision date: January 2005*

The following changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

### **Resection Checklist**

#### **Microscopic**

Phenotyping: "Tumor, Immunophenotyping" was changed to "Phenotyping," as shown below

#### **Phenotyping**

Performed, see separate report

Performed

Specify methods and results: \_\_\_\_\_

Not performed

**Surgical Pathology Cancer Case Summary (Checklist)**

*Protocol revision date: January 2005  
Applies to Hodgkin and non-Hodgkin lymphomas  
of the gastrointestinal tract only  
No AJCC/UICC TNM staging system*

**GASTROINTESTINAL LYMPHOMA: Resection**

Patient name:

Surgical pathology number:

**Note: Check 1 response unless otherwise indicated.**

**MACROSCOPIC****Tumor Site(s)**

Specify, if known: \_\_\_\_\_

 Not specified**\*Tumor Size (largest single mass)**

\*Greatest dimension: \_\_\_ cm

\*Additional dimensions: \_\_\_ x \_\_\_ cm

\* \_\_\_ Cannot be determined (see Comment)

**MICROSCOPIC****Phenotyping** Performed, see separate report Performed

Specify methods and results: \_\_\_\_\_

 Not performed**Histologic Type (WHO Classification)**Hodgkin Lymphoma Nodular lymphocyte predominance Hodgkin lymphoma (NLPHL) Classical Hodgkin lymphoma (CHL) CHL, nodular sclerosis Hodgkin lymphoma (NSHL) CHL, mixed cellularity Hodgkin lymphoma (MCHL) CHL, lymphocyte-rich classical Hodgkin lymphoma (LRCHL) CHL, lymphocyte depletion Hodgkin lymphoma (LDHL)

4

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

Non-Hodgkin Lymphoma Histologic type cannot be assessedB-cell lymphoma B-cell lymphoma, subtype cannot be determined Precursor B-lymphoblastic lymphoma/leukemia Mature B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Lymphoplasmacytic lymphoma Hairy cell leukemia Plasma cell myeloma/ Plasmacytoma Extranodal marginal zone B-cell lymphoma of MALT type Follicular lymphoma, grade 1 (0 to 5 centroblasts per HPF) Follicular lymphoma, grade 2 (6 to 15 centroblasts per HPF) Follicular lymphoma, grade 3 (greater than 15 centroblasts per HPF) Follicular lymphoma, cutaneous follicle center lymphoma Follicular lymphoma, diffuse follicle center cell lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma Burkitt lymphoma/ Burkitt cell leukemia Other (specify): \_\_\_\_\_T-cell Lymphoma T-cell lymphoma, subtype cannot be determined Precursor T-lymphoblastic lymphoma/leukemia T-cell prolymphocytic leukemia T-cell granular lymphocytic leukemia Aggressive NK-cell leukemia Adult T-cell lymphoma/leukemia (HTLV1+) Enteropathy-type T-cell lymphoma Anaplastic large cell lymphoma Peripheral T-cell lymphoma, not otherwise characterized Angioimmunoblastic T-cell lymphoma Other (specify): \_\_\_\_\_**Extent of Involvement** Cannot be assessed Confined to mucosa/submucosa Involvement of muscular wall/subserosa Penetration of serosa, perforation present Penetration of serosa, perforation absent Direct extension to other organ(s) or structure(s) (specify): \_\_\_\_\_ Noncontiguous tumor involvement of other organ(s) or structure(s) absent Noncontiguous tumor involvement of other organ(s) or structure(s) present (specify site[s]): \_\_\_\_\_

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Margins (check all that apply)**

- Cannot be assessed  
 Uninvolved by lymphoma  
 Proximal margin involved by lymphoma  
 Distal margin involved by lymphoma  
 Circumferential (radial or mesenteric) margin involved by lymphoma

**Regional Lymph Nodes**

- Cannot be assessed  
 No regional lymph node involvement  
 Regional lymph node involvement  
 Specify: Number examined: \_\_\_\_  
               Number involved: \_\_\_\_

**Nonregional Lymph Nodes**

- Cannot be assessed  
 No nonregional lymph node involvement  
               Number present in specimen: \_\_\_\_  
 Nonregional lymph node involvement  
               Number present in specimen: \_\_\_\_  
               Number involved: \_\_\_\_

**\*Additional Pathologic Findings (check all that apply)**

- \*  None identified  
 \*  *Helicobacter pylori* gastritis  
 \*  Celiac disease (sprue)  
 \*  Inflammatory bowel disease  
 \*  Other (specify): \_\_\_\_\_

**\*Comment(s)**

6           \* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.